BRÈVE

sur SynBiotic SE (isin : DE000A3E5A59)

SYNBIOTIC Launches Medical Cannabis Pastilles in Germany

SYNBIOTIC SE, a European leader in medical cannabis, announced the launch of cannabis pastilles in Germany. Developed with BOLDER Arzneimittel GmbH & Co KG and partner pharmacies over three years, these pastilles offer a new therapeutic option. With improved delivery and taste, they aim to overcome the disadvantages of current forms, such as dried flowers and extracts.

Daniel Kruse, SYNBIOTIC's Managing Director, emphasized the personalized and effective nature of these pastilles. They offer precise THC dosing and easy application, potentially setting new standards in cannabis-based medicine. Available only on prescription, they are produced in pharmacies according to patient needs.

Subsidaries WEECO Pharma GmbH and MH medical hemp GmbH will distribute the components to pharmacies. Börge Diessel of WEECO Pharma highlighted the timely expansion of the product range complemented by a robust pharmacy network.

R. H.

Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de SynBiotic SE